GM24240
LCL from B-Lymphocyte
Description:
ULLRICH CONGENITAL MUSCULAR DYSTROPHY; UCMD1
COLLAGEN, TYPE II, ALPHA-1; COL2A1
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Muscular Dystrophies CMD Specific |
Class |
Congenital Muscle Diseases |
Biopsy Source
|
Peripheral vein
|
Cell Type
|
B-Lymphocyte
|
Tissue Type
|
Blood
|
Transformant
|
Epstein-Barr Virus
|
Sample Source
|
LCL from B-Lymphocyte
|
Race
|
White
|
Ethnicity
|
Not Hispanic/Latino
|
Ethnicity
|
Polish, Western European
|
Country of Origin
|
USA
|
Family Member
|
1
|
Family History
|
N
|
Relation to Proband
|
proband
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by LINE assay |
|
Gene |
COL6A3 |
Chromosomal Location |
2q37 |
Allelic Variant 1 |
; ULLRICH CONGENITAL MUSCULAR DYSTROPHY; UCMD |
Identified Mutation |
c.6310-2A>G; COL6A3 gene encodes the alpha-3 chain of type VI collagen. |
Remarks |
Clinically affected; progressive proximal weakness; contractures in ankles and knees;distal laxity;hyperkeratosis pilaris; rigid spine; easy fatigability; difficulty swallowing certain types of foods; maximum motor function ever achieved and still maintained: climbs stairs with handrail; holds head up, turns in bed, sits, stands, and walks indoors and outdoors without assistance; cannot run; mild sensory integration issues; behavioral problems; attention difficulties; cognitively bright; slightly elevated CK 400’s; functional mobility score: 3; CMD diagnosis confirmation by CK (blood test, creatine kinase abnormal) and genetic testing; COL6A3 mutation: heterozygous at junction of intron 18 and exon 19 at c.6310-2A>G which is predicted to interfere with the intron 18 splice acceptor site (mutation maybe working in a dominant manner); abnormal MRI /CT scan:"pineal gland cystic appearance, no mass present"; EMG myopathic. |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not Inactivated |
Substrate |
None specified |
Subcultivation Method |
dilution - add fresh medium |
Supplement |
- |
|
|